Aberrant activation of the Wnt pathway is observed in numerous cancers, and is particularly important in colon cancer. We demonstrate that Rac1 GTPase can significantly increase the signaling activity of b-catenin in cells with inherent dysregulation of the canonical Wnt signaling pathway. Expression of dominant-negative (N17)Rac1 mutant in colon cancer cells caused a marked inhibition of Wnt signaling, as determined by the TCF/LEF-responsive (TOPFLASH) transcription assay. Expression of a constitutively active (V12)Rac1 mutant caused up to 40-fold induction from the TOPFLASH promoter, and this was dependent on the presence of stabilized b-catenin. This induction was completely blocked by the expression of dominant-negative TCF-4, suggesting that b-catenin and TCF-4 complex formation is required for Rac1-mediated transcription. Furthermore, we show that Cyclin D1, an important biological Wnt target gene, is regulated by Rac1 in a b-catenin/TCF-dependent manner. We observed that Rac1 co-immunoprecipitates with b-catenin and TCF-4 only in its active GTP-bound form. Both cell fractionation studies and fluorescence microscopy indicate that overexpression of V12Rac1 results in increased cytosolic and nuclear expression of b-catenin. Interestingly, mutation of the polybasic region of Rac1, which prevents its nuclear localization, also caused an appreciable decrease in nuclear localization of b-catenin, and effectively abolished its b-catenin-dependent transcription co-activator function. Taken together, our data demonstrate a novel mechanism of Wnt pathway regulation whereby activation of Rac1 amplifies the signaling activity of stabilized/mutated b-catenin by promoting its accumulation in the nucleus, and synergizing with b-catenin to augment TCF/LEF-dependent gene transcription.
Introduction
Rho GTPases, of which Rac1, RhoA, and Cdc42 are most well characterized, are important members of the Ras superfamily of small GTP-binding proteins, implicated in cellular processes primarily involving cytoskeletal reorganization (Hall, 1998) . The Rac1 GTPase is emerging as an important participant in a variety of signaling pathways such as mitogen-activated protein kinase (MAPK), c-Jun N-terminal kinase/stress activated kinase (JNK/SAPK), nuclear factor kB (NF-kB) and phosphatidylinositol 3-kinase (PI-3K) (Coso et al., 1995; Perona et al., 1997; Murga et al., 2002) . Activation of these various signaling cascades allows Rac1 to regulate a diverse set of normal cellular processes including intercellular adhesion, cytoskeletal membrane ruffling and lamellipodia formation, proliferation, and gene transcription (Sahai and Marshall, 2002) .
There is mounting evidence to suggest that Rac1 may also be involved in tumorigenesis. In vitro studies have implicated Rac1 in cell migration, cell-cycle progression, and Ras-induced focus formation, suggesting a role for Rac1 in the formation and progression of tumors (Sahai and Marshall, 2002) . The Rac1-specific upstream activator, Tiam1, induces invasion in the T-lymphoma cell system (Habets et al., 1994) . Although mutations have not been reported, overexpression of Rac1 occurs in several different types of tumors including breast, colon, and lung (Fritz et al., 1999; Jordan et al., 1999) . Furthermore, a novel Rac1 splice variant, Rac1b, is highly expressed in colon and breast tumors and is thought to function in accelerated GDP-GTP exchange, thereby mimicking the phenotype of a constitutively active mutant (Schnelzer et al., 2000) .
Extensive studies into the molecular etiology of cancer have established a central role for the Wnt signal transduction pathway (Polakis, 2000) . This pathway is evolutionarily conserved and controls many cellular events during normal embryological development including proliferation, morphology, and cell fate decisions. b-Catenin is the key effector of the canonical Wnt pathway. Binding of a specific subset of Wnt ligands to their cognate frizzled receptors initiates a chain of signaling events that culminates in the nuclear translocation of b-catenin and its heterodimerization with members of the T-cell factor (TCF)/lymphoid enhancing factor (LEF) family of HMG-box transcription factors and subsequent transcription of specific target genes. In the absence of a Wnt stimulus, b-catenin is maintained at low concentrations in the cytoplasm and nucleus via its interaction with a complex of proteins including adenomatous polyposis coli (APC) tumor suppressor protein, axin, protein phosphatase 2A (PP2A) and glycogen synthase kinase-3b (GSK-3b). Phosphorylation by GSK-3b targets b-catenin for ubiquitination and subsequent degradation by the proteasome (Seidensticker and Behrens, 2000) . Mutations in any one of these critical Wnt components can interfere with the degradative control of b-catenin leading to constitutive Wnt signaling. As a result, bcatenin-TCF/LEF transcription factor complexes form and aberrantly activate transcription of several genes involved in cell proliferation including cyclin D1 and cmyc (Roose and Tetsu and McCormick, 1999) . In colon cancer, the aberrant activation of Wnt target genes is thought to coerce intestinal cells into a hyperproliferative state, representing the initial steps towards onset of cancer.
The simplistic view of a linear model of Wnt pathway activation has rapidly evolved in recent years into a rather intricate network. Significant milestones include the discovery of noncanonical routes downstream of Frizzled receptor engagement, such as the planar-cellpolarity and Wnt/Ca 2 þ pathways (Huelsken and Birchmeier, 2001 ). Furthermore, identification of novel functional interactions for key canonical Wnt players such as b-catenin, APC, and TCF/LEF, implicates additional signaling pathways as potential regulators of the canonical Wnt pathway (Ishitani et al., 1999; Zorn et al., 1999; Nishita et al., 2000; Sampson et al., 2001) . For example, Rho and Rac1 GTPases have been implicated in noncanonical Wnt signaling, to influence cell polarity and morphogenetic movements during vertebrate gastrulation (Malliri and Collard, 2003) . In addition, activated Rac1 has been shown to modulate cell-cell adhesion dynamics by stabilizing the b-catenin : E-cadherin complex (Fukata et al., 1999) . Although Rac1 has been implicated in tumorigenesis, the mechanisms and pathways by which Rac1 may influence this process remains elusive. In this regard, we investigated whether Rac1 could also modulate b-catenin function in the context of the canonical Wnt signaling pathway.
Results

Rac1 is activated in several cancer cell lines
To investigate the involvement of Rac1 GTPase in regulation of the Wnt pathway, we first examined its activation status in a panel of cancer cell lines known to exhibit dysregulated canonical Wnt signaling, either due to mutations of APC (SW480, Caco-2) or b-catenin (HCT116), or decreased GSK-3b activity (PC3). We also included cells with intact and tightly regulated Wnt signaling (293) as well as breast (MCF-7, T47D), prostate (PC3), and pancreatic (Capan-1) cancer cell lines in our analysis. With the exception of PC3 cells, activated Rac1-GTP was detected in all colon, breast, and pancreatic cancer cell lines, and only minimally in 293 cells despite its expression in whole-cell lysates (Figure 1 ).
Rac1 stimulates TCF/LEF reporter activity
Robust expression of activated Rac1 in HCT116 and SW480 colon carcinoma cells led us to next investigate whether Rac1 was functionally contributing to Wnt signal transduction in these cells. We initially examined the effect of blocking endogenous Rac1 activity, by transient transfection of a dominant-negative mutant N17Rac1, on regulation of b-catenin-TCF/LEF transcriptional co-activator function. As shown in Figure 2a , basal activity of the TCF-responsive promoter, TOP-FLASH, is very high in HCT116 cells, due to a stabilizing mutation in one b-catenin allele that results in constitutive Wnt signaling . However, expression of N17Rac1 resulted in approximately 40% inhibition of TOPFLASH activity, indicating that endogenous Rac1 was contributing to the TCF-mediated transcriptional response in these cells. Conversely, expression of a constitutively activated mutant, V12Rac1, that is defective in intrinsic GTPase activity and exists constitutively in the GTP-bound (i.e. activated) form, caused a dramatic dose-dependent induction of TCF reporter activity, up to 2.5-fold (Figure 2b ). Expression of wild-type Rac1 only minimally induced TOPFLASH activity, demonstrating that activation of Rac1 is required for the transcriptional response. We sought to obtain additional evidence supporting the activator function of Rac1 in SW480 and 293 cells, which have aberrantly active and tightly regulated Wnt signaling, respectively. Similar to HCT116 cells, overexpression of V12Rac1 caused a two-fold induction of TCF reporter activity in
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Blot: anti-Rac1 G T P γ S 2 9 3 H C T 1 1 6 S W 4 8 0 C a c o -2 M C F -7 T 4 7 D P C 3 C a p a n -1 Figure 1 Endogenous expression of activated Rac1 in various cancer cell lines. Activation status of Rac1 was determined in a panel of human cell lines: 293 (embryonic kidney), HCT116, SW480, Caco-2 (colon carcinoma), MCF-7, T47D (breast cancer), PC3 (prostate cancer), and Capan-1 (pancreatic cancer). Top Panel: Activated Rac1-GTP level was determined by GST pulldown assays using the PAK binding domain (PBD), followed by immunoblot analysis using anti-Rac1 antibody. Bottom Panel: Total Rac1 expression was determined by immunoblot analyses of whole-cell lysates (20 mg). Data shown are representative of three independent experiments
Rac1-mediated activation of the canonical Wnt Pathway S Esufali and B Bapat SW480 cells (Figure 2c ). In contrast, V12Rac1 did not induce TOPFLASH activity in 293 cells (Figure 4c (Schmitz et al., 2000) . Therefore, we next investigated whether activated mutants of Cdc42 (V12Cdc42) and RhoA (V14RhoA) could also activate TCF/LEF-mediated transcription.
As shown in Figure 3a , neither V12Cdc42 nor V14RhoA overexpression stimulated TOPFLASH activity. Protein expression of the Rho GTPase was confirmed by Western blotting (shown in inset). Therefore, regulation of downstream Wnt signaling appears to be specific for Rac1 and is not a shared attribute of the other Rho GTPases. Numerous signaling pathways have been identified as downstream targets of Rac1 activation (Coso et al., 1995; Frost et al., 1996) . To evaluate the sensitivity of Wnt pathway induction by Rac1, we tested the ability of V12Rac1 to activate the MAPK and JNK pathways, known downstream targets of Rac1 activation, in HCT116 cells. As depicted in Figure 3b , V12Rac1 was able to activate AP-1 and SRF-dependent gene transcription, corresponding to MAPK and JNK pathway activation, respectively, to similar levels as TCF/LEF-responsive TOPFLASH transcription. We also included cAMP-dependent protein kinase A (PKA) pathway activation, known to act upstream of Rac1, in our analysis (O'Connor and Mercurio, 2001) . As predicted, V12Rac1 did not activate the PKAresponsive promoter, CRE-Luc (Figure 3b ), while cotransfection of PKA expression vector resulted in approximately four-fold activation (data not shown). This indicates that Rac1 can activate distinct signaling pathways with comparable levels of sensitivity in HCT116 cells.
Rac1 and b-catenin stimulate transcription in a cooperative manner
To determine if b-catenin-TCF complex formation is necessary for mediating Rac1's effects, we utilized a dominant-negative mutant of TCF-4 (DNTCF) that effectively blocks b-catenin-mediated TCF-dependent transcription . As depicted in Figure 4a , expression of DNTCF completely blocked V12Rac1's ability to stimulate TCF reporter activity, indicating involvement of TCF-4 and indirectly, that of Figure 4c , expression of D89b-cat resulted in a maximal nine-fold activation of TOPFLASH activity, achieved at the lowest dose administered, indicating that the capacity of Wnt pathway induction by stabilized b-catenin was already maximized at the lowest dose. Although ineffective on its own, when the same doses of V12Rac1 were cotransfected with the lowest dose of D89b-cat, we observed a remarkable dose-dependent induction of TOPFLASH activity, ranging from 11-to 40-fold, clearly indicating that Rac1 synergizes with b-catenin to augment the latter's transcriptional co-activator function.
Next, we wished to corroborate the observed crosstalk of Rac1 and b-catenin signaling, with a biological target gene. The cyclin D1 gene has been established as a key transcriptional target of the Wnt/b-catenin pathway through a TCF-4/LEF-1 binding site present in the cyclin D1 promoter (Tetsu and McCormick, 1999) . Interestingly, Rac1 has previously been implicated in cyclin D1 gene expression via activation of NF-kB (Joyce et al., 1999) . As shown in Figure 4d , basal expression from a full-length cyclin D1 promoter (À1745CD1LUC) is high in HCT116 cells, likely because of constitutive Wnt signaling. This is supported by the substantial dose-dependent inhibition of cyclin D1 promoter activity (up to 50%) by expression of DNTCF. WTb-catenin only modestly enhances cyclin D1 promoter activity, suggesting maximal induction of transcription from the TCF/LEF transcription factor response element present in the cyclin D1 promoter. V12Rac1 stimulated cyclin D1 promoter activity in a dose-dependent manner, up to 2.6-fold, that could be completely abrogated by co-expression of DNTCF. These results indicate that Rac1 and b-catenin/TCF are linked in a common pathway that regulates cyclin D1 gene transcriptional activity. Furthermore, inhibiting endogenous Rac1 activity in HCT116 cells, by expression of dominant-negative N17Rac1, results in a time-dependent inhibition of growth ( Figure 4e ).
Expression of constitutively active Rac1 alters the intracellular distribution of b-catenin
To understand the mechanism of Rac1-mediated activation of b-catenin/TCF signaling, we examined the subcellular distribution of b-catenin in V12Rac1-transfected HCT116 cells by immunofluorescence microscopy. In untransfected cells, highest levels of endogenous b-catenin were observed at the cell membrane, specifically at regions of cell-cell contact ( Figure 5a ). In contrast, cells transfected with V12Rac1 displayed decreased b-catenin staining at sites of cell-cell contact and a considerable increase of 
(e) HCT116 cells were transfected with N17Rac1 for indicated time points, followed by quantitation of cell proliferation status. Data are plotted as the ratio of N17Rac1-transfectants vs empty vector-transfectants for each time point, and proliferation status at time ¼ 0 was designated as 100%. Each data point represents the average of quadruplicate values. (a-e) Results presented are representative for at least three independent experiments
Rac1-mediated activation of the canonical Wnt Pathway S Esufali and B Bapat cytosolic or membrane pools of b-catenin were not detected by this method, a significant increase in nuclear b-catenin was observed in V12Rac1-transfected cells (Figure 5c ). Considered together, these data suggest that activated Rac1 triggers redistribution of cellular b-catenin, culminating in its nuclear accumulation.
PBR region of Rac1 important for mediating b-catenin/ TCF target gene transcription
It is widely accepted that Rac1 is a cytosolic protein, primarily functioning at the plasma membrane to regulate various physiological processes such as actin cytoskeletal remodeling. However, a recent report challenges this view, demonstrating the presence of Rac1 in the nuclear compartment of cells (Lanning et al., 2003) . Our data support the nuclear localization of Rac1. We observed nuclear expression of transfected V12Rac1, by both microscopy ( Figure 5b ) and Western blotting of nuclear lysates in HCT116 cells (Figures 5c  and 6a ). We also observed nuclear expression of endogenous Rac1 by immunoblot analysis (data not shown). To confirm proper fractionation, blots were stripped and reprobed for Topoisomerase II and paxillin expression, which are known nuclear and cytoplasmic marker proteins, respectively (Figure 6a ) (Wang, 1985; Salgia et al., 1995) . Nuclear localization of Rac1 likely occurs via a signal sequence present at its C-terminus denoted the polybasic region (PBR). This region was recently shown to enhance the nuclear accumulation of Rac1-mediated activation of the canonical Wnt Pathway S Esufali and B Bapat protein complexes containing armadillo domain-containing proteins such as SmgGDS and p120-catenin and Rac1 (Lanning et al., 2003) . We hypothesized that Rac1 may regulate nuclear accumulation of b-catenin, also an armadillo-domain containing protein, in a similar manner. As anticipated, mutation of the PBR region of V12Rac1 by substitution with glutamine residues, (denoted V12Rac1PBRQ) largely compromised its nuclear localization capability (Figure 6b ). Furthermore, mutation of PBR abolished V12Rac1's ability to synergize with b-catenin to mediate downstream Wnt target gene transcription (Figure 6c ). The absence of transcriptional regulation by V12Rac1PBRQ was not due to a deficiency in GTP loading (Figure 6d ). Similar to V12Rac1, expression of V12Rac1PBRQ resulted in increased cytosolic staining of b-catenin in HCT116 cells examined by fluorescence microscopy. However, an appreciable decrease in nuclear staining of b-catenin was activated Rac1-GTP levels was determined by GST pull-down assays using the PAK binding domain (PBD), followed by immunoblot analysis using anti-Rac1 antibody. Bottom Panel: cellular expression of cDNAs was confirmed by immunoblot analysis of whole-cell lysates with appropriate tag antibodies (10 mg). Lanes indicated are GTPgS (1 -positive control); GDP (2 -negative control); myctagged N17Rac1 (3); myc-tagged V12Rac1 (4); HA-tagged WTRac1PBRQ (5); and HA-tagged V12Rac1PBRQ (6). (E) Deconvolution microscopy shows increased cytosolic but diminished nuclear expression of b-catenin in V12Rac1PBRQ-transfected HCT116 cells. Cells were stained with Hoescht dye to identify nuclei (Panel A), anti-HA antibody to detect HA-tagged V12Rac1PBRQ (panel B), and anti-b-catenin antibody (panel C). Solid white arrows indicate V12Rac1PBRQ-transfected cells (note the reduced nuclear expression). Cytosolic b-catenin expression is increased in V12Rac1PBRQ-transfectants, with a noticeable decrease in nuclear staining (unfilled triangles) observed (denoted by arrows in panel C of Figure 6e ). Altogether, these data suggest a critical role for the PBR in mediating Rac1's nuclear localization and transcriptional co-activator function on b-catenin.
Activated Rac1 associates with b-catenin and TCF-4
Next, to see if Rac1 can physically interact with bcatenin and/or TCF-4, epitope-tagged Rac1 constructs were transfected into HCT116 cells, and cell lysates were subsequently immunoprecipitated with antibody specific for b-catenin or TCF-4. Co-precipitation of Rac1 proteins was detected by immunoblotting with tagspecific antibodies. FLAG-tagged V12Rac1 co-immunoprecipitated with endogenous b-catenin and TCF-4, while no association was detected with myc-tagged N17Rac1, and only a weak association with myc-tagged wild-type Rac1 (Figure 7a ). Under reverse conditions, immunoprecipitation using a FLAG-specific antibody to recognize transfected FLAG-tagged V12Rac1 'pulled-down' b-catenin, confirming the specificity of the interaction (Figure 7b ). Similarly, association of V12Rac1 with b-catenin was observed in 293 cells, demonstrating that the interaction is not unique to tumor cells (data not shown). In vitro binding assays using purified recombinant activated mutant of Rac1 fused to GST (GST-L61Rac1) failed to precipitate bcatenin from HCT116 lysates, indicating that the interaction between Rac1 and b-catenin is not a direct one, and likely involves other factors ( Figure 7c ). As a positive control, blots were stripped and re-probed with PAK1 antibody, a known interactor of active Rac1. In addition, co-immunoprecipitation studies demonstrated a lack of association of V12Cdc42 or V14RhoA with bcatenin or TCF-4 (data not shown). Taken together, these data demonstrate that b-catenin and TCF-4 associates specifically with the Rac1 subtype of Rho GTPases, and binds only when Rac1 is in the active GTP-bound conformation.
Discussion
The Wnt pathway is emerging as a signaling network rather than a linear pathway, integrating multiple extracellular stimuli and intracellular pathways to coordinate distinct physiological functions. A major breakthrough was the finding that different classes of Wnt ligands could transduce intracellular signals via two distinct routes, and hence the terms 'canonical' and 'noncanonical' were coined to describe the b-cateninmediated and b-catenin-independent pathways of Wnt signaling, respectively (Huelsken and Birchmeier, 2001 HCT116 cells transfected with empty vector (À) or V12Rac1-FLAG ( þ ), subjected to immunoprecipitation with indicated antibodies, followed by Western blot analysis probing for V12Rac1 (detected by FLAG antibody) or b-catenin. As a negative control, WCL were immunoprecipitated with agarose beads alone. (c) Binding assay was performed using purified recombinant GSTL61Rac1 protein or GST alone (negative control) bound to glutathione-sepharose beads and HCT116 whole-cell lysates. Binding reactions were separated by SDS-PAGE and Western blotted with indicated antibodies. For (a-c), data shown are representative for three independent experiments Rac1-mediated activation of the canonical Wnt Pathway S Esufali and B Bapat signal for Rac1 to 'switch gears' and divert from noncanonical to canonical signaling. We observed high levels of activated Rac1 in a panel of cancer cell lines (Figure 1 ). Elevated levels of Rac1 have also been reported in several tumor types including breast, lung, and colon (Fritz et al., 1999) . Thus, the activation of Rac1 may represent a common step of tumorigenesis. A grave consequence of aberrant Wnt signaling is constitutive transcriptional activation of b-catenin/TCF target genes, believed to be critical in the initial development of many cancers (Polakis, 2000) . Using overexpression of constitutively active and dominant-negative Rac1 mutants, we demonstrate that Rac1 can significantly modify b-catenin-TCF/LEF transcriptional activity. Expression of activated mutant V12Rac1 stimulated b-catenin/ TCF-mediated transcriptional activation in colon cancer cell lines HCT116 and SW480, containing elevated levels of b-catenin due to mutations in b-catenin or APC genes, respectively. Conversely, expression of dominant-negative N17Rac1 mutant resulted in marked inhibition of endogenous Wnt signaling, illustrating the functional contribution of endogenous Rac1 activity in propagating Wnt signaling in these cells (Figure 2) .
Our data suggest that dysregulated and consequently elevated b-catenin levels are a prerequisite for Rac1 to elicit its stimulatory effects. V12Rac1 was unable to stimulate transcription from the TCF/LEF-responsive TOPFLASH promoter in 293 embryonic kidney cells, which have normal Wnt signaling and therefore low levels of cellular b-catenin. However, co-transfection of V12Rac1 and stabilized b-catenin into these cells resulted in a considerable activation of transcription from the TCF/LEF-responsive TOPFLASH promoter. In fact, while mutant b-catenin induced transcription maximally up to nine-fold, co-expression of activated Rac1 resulted in a marked dose-dependent induction of transcription up to 40-fold. These results demonstrate a clearly robust synergistic association between Rac1 activity and b-catenin stability/accumulation in order to drive downstream transcriptional events in the Wnt signaling cascade. We observed a modest additive transcriptional response between V12Rac1 and b-catenin in HCT116 cells likely because of high endogenous levels of b-catenin. A similar mechanism has been proposed for heterotrimeric G proteins, G a 12 and G a 13, and also for IQGAP1, which enhances transcriptional co-activator function of b-catenin only in cells containing elevated b-catenin levels (Meigs et al., 2001; Briggs et al., 2002) . IQGAP1 is a downstream target of Rac1, and it is therefore tempting to speculate that Rac1 may mediate its stimulatory effects on TCFmediated transcription via activation of IQGAP1 and warrants future investigation (Kuroda et al., 1998) . Alternatively, numerous other specific downstream effectors of Rac1 are known, such as PAK, WASP, IQGAP2, Sra-1, and POSH, and should not be excluded as possible downstream targets in the stimulation of transcription of Wnt pathway genes (Aspenstrom, 1999) .
Most regulators of the canonical Wnt pathway do so by altering cytoplasmic b-catenin stability and turnover. APC, axin, Siah-1, and PP2A are a few examples of proteins that modify the half-life of b-catenin and thereby alter b-catenin/TCF co-transcriptional activity (Munemitsu et al., 1995; Kishida et al., 1998; Seeling et al., 1999; Liu et al., 2001) . Until recently, it was widely accepted that cells harboring a single stabilizing mutation in a b-catenin allele undergo maximal b-catenin stabilization. However, recent reports challenge this view, suggesting that b-catenin mutations, such as Ser45 in HCT116 cells, only partially stabilizes the protein, since phosphorylation may still take place at three other serine residues, that are similarly protective against degradation (Chan et al., 2002) . Furthermore, b-catenin could still be synthesized from the other wild-type allele. Thus, we cannot exclude the possibility that Rac1 may potentiate further b-catenin stabilization in HCT116 cells to mediate its stimulatory effects, and this warrants future investigation.
Cytoskeletal reorganization by Rac1 is a wellcharacterized function, and may play a role in mediating the effects on enhanced b-catenin signaling. Our microscopy data, showing diminished staining of membrane b-catenin in V12Rac1-transfected cells, support this view. b-Catenin is linked to the actin cytoskeleton through association with a-actinin. Rac1 may mediate redistribution of the membrane b-catenin pool by modifying this interaction. In addition, microscopy experiments also demonstrated an overall increase in b-catenin expression, both in the cytoplasm and within the nucleus of V12Rac1-transfected HCT116 cells. We also observed increased b-catenin in the nuclear fraction of V12Rac1-transfected cells by immunoblot analysis (Figure 5c ). However, we did not detect similar changes in the membrane or cytoplasmic pool of b-catenin by immunoblot analysis. This is likely due to the lower sensitivity of the assay as well as the transfection efficiency (approximately 60%). Taken together, our data suggest that expression of activated Rac1 results in both increased cytosolic b-catenin, and also promotes its accumulation in the nucleus, where it couples with TCF/LEF to activate transcription of Wnt target genes. The source of the additional b-catenin, whether from the membrane pool and/or due to further stabilization, is unclear, and is presently being addressed.
Rac1 was recently identified to have a functional nuclear localization signal sequence present at the Cterminus denoted the polybasic region (PBR), found to enhance the nuclear accumulation of protein complexes containing SmgGDS and Rac1 (Lanning et al., 2003) . Nuclear expression of V12Rac1PBRQ mutant was significantly decreased in HCT116 cells (Figure 6 ). This was accompanied by a concomitant decrease in nuclear localization of endogenous b-catenin, supporting a nuclear chaperone role for Rac1, mediated via its PBR. Consistent with these findings, mutation of the PBR completely abolished the synergistic relationship between Rac1 and b-catenin, underscoring the impor-tance of the PBR in mediating Rac1 transcriptional coactivator function.
We propose a model whereby dysregulation of b-catenin, an event that occurs early in many cancers, can trigger cross-talk with active Rac1, in a manner which further amplifies downstream b-catenin/TCF target gene transcription. Active Rac1 leads to increased cellular b-catenin, and its subsequent nuclear accumulation, where it associates with TCF/LEF transcription factors (Figure 8 ). Rac1 may increase cellular b-catenin by recruiting it from the membrane pool or further stabilization of cytosolic pool. Whether physical association of activated Rac1 with b-catenin and TCF/LEF facilitates nuclear translocation or retention of b-catenin, or augments its transcriptional co-activator function, requires further investigation. However, it is clear that the PBR domain of Rac1 is important for one or more of these steps. Association of Rac1 with b-catenin/TCF may alter the specificity of the transcription factor complex to control expression of a specific subset of Wnt target genes. TCF/LEF binding sites present in promoter regions may represent a convergence point for many different signaling pathways in addition to the Wnt pathway. For example, TCF function can be regulated by interaction with transcription factors other than b-catenin, such as Groucho and Smads (Sharpe et al., 2001) . Rac1 is known to activate a multitude of signaling pathways including the NF-kB, PI3-K, and MAPK pathways, leading to transcription of specific genes. It is exciting to speculate that one or more Rac1-specific pathways may converge with the Wnt pathway at the level of TCF activation to coordinate gene transcription. This may in fact be the case with the cyclin D1 gene, a key transcriptional target of Wnt signaling, which we demonstrate can be upregulated by Rac1 in a b-catenin/TCF-dependent manner.
It is becoming increasingly clear that Rac1 may play a significant role in the transforming capabilities of cells, although the precise mechanism is presently unresolved. Our studies suggest that nuclear accumulation of b-catenin and concomitant amplification of b-catenin/TCF target gene transcription may be one mechanism by which Rac1 contributes to cellular transformation. Rac1 may provide additional signals and thus generate distinct expression profiles of b-catenin-TCF target genes, thereby contributing to more specific and precise regulation of tumor progression driven by the Wnt pathway. We have also observed that expression of N17Rac1 results in approximately 40% reduction of cell proliferation of HCT116 cells (Figure 4e ). Thus, Rac1-mediated Wnt signaling may alter the proliferation state of cells hence affecting overall tumor growth. Identifying the cellular signals that determine whether Rac1 functions in noncanonical vs canonical Wnt signaling will further our knowledge and understanding of the complexities of this signaling network.
Materials and methods
Materials
Tissue culture reagents and fetal bovine serum were purchased from Invitrogen Life Technologies (Burlington, Ontario T47D and PC3 cells were cultured in RPMI. All cell culture media was supplemented with 10% fetal bovine serum. All cell lines were cultured at 371C in a humidified atmosphere of 5% CO 2 except SW480, which was grown in the absence of CO 2 .
Rac1 activation assay
Rac1-GTP levels were determined using a nonradioactive Rac activity Assay kit (Upstate Biotechnology). Briefly, cell lysates were immunoprecipitated with a GST fusion-protein corresponding to the p21-binding domain (residues 67-150) of human PAK1 bound to glutathione-agarose, run on 12% SDS-PAGE, and Western blotted using monoclonal anti-Rac1 antibody. In vitro GTPgS and GDP protein loading were included for positive and negative controls, respectively.
Luciferase reporter gene assays
Transfection experiments were carried out using Lipofectamine 2000 reagent (Invitrogen Life Technologies), according to the manufacturer's instructions. Cells were seeded in 24-well plates at a density of 2 Â 10 5 cells per well 24 h prior to transfection. Luciferase constructs (0.1 mg) containing either four tandem wild-type (pTOPFLASH) or mutant (pFOP-FLASH) TCF-4 binding sites, cyclin D1 (À1745) promoter, AP-1-LUC, CRE-LUC or SRF-LUC were transfected into cells to determine luciferase reporter activity . In addition, cells were co-transfected with an internal control (0.03 mg of pCMVb-gal), along with combinations of WT/V12 (activated)/N17 (dominant-negative) Rac1, WT-or V12-Rac1PBRQ mutants, V12Cdc42, V14RhoA, WT or activated mutant (D89) b-catenin, or dominant-negative TCF-4 (DNTCF). The total amount of DNA per transfection was held constant at 1 mg total plasmid DNA by cotransfection of appropriate amounts of empty vector. Luciferase and b-galactosidase activity was measured 24 h after transfection using commercially available kits from Promega (Madison, WI, USA) and Stratagene, respectively. Luminescence was quantitated using a Berthold 96-well microplate luminometer. All transfections were carried out in triplicate on at least three independent occasions, and error bars represent s.e.m. (standard error of the mean).
Immunoprecipitation, cell fractionation, and Western blotting Cell extracts were prepared using RIPA buffer (0.5%. Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 1 Â PBS, 'Complete' mini EDTA-free protease inhibitor tablet (Roche, Mannheim, Germany)). Immunoprecipitation was conducted using 300 mg of cell lysate, 2 mg of TCF-4 antibody (Upstate Biotechnology) or b-catenin antibody (Transduction Labs, Lexington, KY, USA), and 50 ml of Protein A/G agarose (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Immunocomplexes were washed three times using RIPA buffer, resuspended in Laemmli buffer, and resolved on a 10% SDS-PAGE gel. Resolved proteins were transferred onto PVDF nylon membranes (Amersham Pharmacia Biotech, Quebec, Canada), and nonspecific reactivity was blocked with Tris-buffered saline containing 0.1% Tween-20 and 5% non-fat dried milk. Antibodies specific for FLAG (Sigma, St Louis, MO, USA), Myc tag (Santa Cruz Biotechnology) and b-catenin were used according to the manufacturer's specifications. Bound proteins were detected by using appropriate horseradish peroxidase-conjugated secondary antibodies in the enhanced chemiluminescence system (Amersham Pharmacia Biotech). For cell fractionation analysis, cells were separated into either cytoplasmic and nuclear fractions, or membrane fractions, using the NE-PER and MEM-PER kits, respectively (Pierce, Rockford, IL, USA). Briefly, cells were grown in 60 mm dishes until approximately 80% confluence prior to transfection. At 24 h post-transfection, cells were processed according to the manufacturer's instructions. Cytoplasmic and nuclear fractions (30 and 10 mg, respectively) or membrane fractions (10 mg) were separated on 10% SDS-PAGE and immunoblotted with indicated antibodies.
Cell proliferation assay
HCT116 cells were transfected in 96-well plates with either EV or N17Rac1. Cells were harvested for proliferation status at 0-96 h after transfection, using Celltitre 96 Aqueous One Solution Cell Proliferation Assay, following the manufacturer's instructions (Promega). Each time point was based on four replicates, and the experiment was conducted three independent times.
Immunocytochemistry
HCT116 cells cultured on glass coverslips were transfected with FLAG-tagged V12Rac1 or hemagglutinin (HA)-tagged V12Rac1PBRQ. After 24 h, cells were fixed in paraformaldehyde (4%, 15 min, RT) and permeabilized in Triton X-100 (0.2%, 5 min, RT). Cells were incubated in blocking buffer (10% goat serum, 1 h, RT) followed by incubation with mouse anti-b-catenin monoclonal, rabbit anti-FLAG polyclonal (Sigma), and mouse FITC-conjugated anti-HA (SIGMA) primary antibodies. After washing with PBS, cells were incubated with FITC-or Texas Red-conjugated anti-mouse or anti-rabbit antibodies (Molecular Probes, Eugene, OR, USA). Nuclei were stained with Hoechst 33342 dye for 5 min (1 : 2000 dilution of 1 mg/ml stock, Molecular Probes).
Cells were washed, mounted in phosphate-buffered saline containing 50% glycerol and 0.1% p-phenylenediamine and examined using a Leica DMRX fluorescence microscope. The level of nonspecific background immunostaining was established by omitting primary antibodies. In addition, high-resolution images were obtained by using a Leica TCS Sp2 confocal microscope ( Â 60 lens magnification) or Olympus 1X-70 inverted deconvolution microscope ( Â 100 lens magnification).
